Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Operating Expenses (2016 - 2025)

Bioadaptives' Operating Expenses history spans 7 years, with the latest figure at $255700.0 for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 24.2% to $255700.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 74.0% increase, with the full-year FY2025 number at $1.1 million, up 74.0% from a year prior.
  • Operating Expenses hit $255700.0 in Q4 2025 for Bioadaptives, down from $269540.0 in the prior quarter.
  • Over the last five years, Operating Expenses for BDPT hit a ceiling of $337339.0 in Q4 2024 and a floor of $20955.0 in Q1 2023.
  • Historically, Operating Expenses has averaged $148787.1 across 5 years, with a median of $133695.5 in 2022.
  • Biggest five-year swings in Operating Expenses: soared 820.62% in 2021 and later tumbled 88.11% in 2023.
  • Tracing BDPT's Operating Expenses over 5 years: stood at $178876.0 in 2021, then crashed by 84.16% to $28332.0 in 2022, then skyrocketed by 127.6% to $64483.0 in 2023, then surged by 423.14% to $337339.0 in 2024, then fell by 24.2% to $255700.0 in 2025.
  • Business Quant data shows Operating Expenses for BDPT at $255700.0 in Q4 2025, $269540.0 in Q3 2025, and $280282.0 in Q2 2025.